Finally, the authors argued that the potential beneficial effect of DMT in MS is based on the downregulation of pro-inflammatory cytokines and the reduction of immune responses through interferons-beta, IL-1beta, IL-6, and TNF-alfa. The gene discussed is IL6; the disease is myeloid sarcoma.